HCV NS3/4A Protease Inhibitors
DBCAT004186Pharmacologic class
A DrugBank category of 7 drugs. 7 of them are approved.
What you can answer from here — as of September 06, 2018
Which targets do HCV NS3/4A Protease Inhibitors share, and which companies have late-stage candidates in this class?
Create a free account or log in to explore the full data card.
Create Account